Our results highlight three major aspects contributing to the tumor resistance to sPKIs and consequent failure of these drugs in the treatment of glioblastoma: the inter-tumoral heterogeneity, the presence of constantly active bypass signals derived mainly from the activation of the ErbB pathway, and the influence of the preclinical evaluation of the drugs in different model systems. Here, EGFR is linked to glioblastoma.